Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 26, 2017 in Melanoma | 0 comments

In a nutshell

This study examined the effectiveness of isolated limb perfusion (ILP) in locally advanced melanoma. Researchers suggested that ILP was safe and effective in these patients.

Some background

Surgery, chemotherapy and radiation therapy are the standard treatments for advanced melanoma. However, ILP has been shown to increase the rates of tumor response. ILP involves a highly concentrated chemotherapy given to a specific part of the body. The effectiveness of ILP in the treatment of advanced melanomas is still being investigated.

Methods & findings

The objective of this study was to evaluate the effectiveness of ILP in the treatment of advanced melanomas.

This study included information on 163 patients with melanoma (72.1%), sarcoma (23.4%), squamous cell carcinoma (SSC; 2.0%) and merkel cell carcinoma (MCC; 2.5%).

The average follow-up time was 21.8 months. The overall response rate (response such as tumor shrinkage) for melanoma was 59%.

Patients with melanoma who responded to ILP had a longer progression-free survival (time from treatment to cancer progression) of 14.1 months when compared to 3.2 months for patients that did not respond to the treatment. Melanoma patients also showed an increased overall survival (time from treatment until death from any cause; 56 months) when compared with non-responders (26.7 months).

The bottom line

This study suggested that ILP is a safe option to treat advanced melanoma patients. 

The fine print

This study did not take into account the effect of other treatments before or after receiving ILP. 

Published By :

Annals of Surgical Oncology

Date :

Oct 10, 2017

Original Title :

Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions.

click here to get personalized updates